Pfizer has announced it will stop enrolment in a clinical trial for Paxlovid – its COVID-19 antiviral pill – for standard-risk COVID-19 patients after the latest results suggested the drug did not reduce symptoms or hospitalizations and deaths to a statistically significant degree.
Paxlovid, which consists of two different antiviral drugs – nirmatrelvir and ritonavir – is currently approved or authorized for conditional or emergency use in more than 65 countries, including the United States, to so called treat COVID-19 patients at high risk of severe illness, including hospitalization or death.
Pfizer said on June 14 that it will cease enrollment into the EPIC-SR trial due to low rate of hospitalization or death in the standard-risk population.
